Peri-operative Alemtuzumab (Campath-1H) and Plasmapheresis for High-PRA Positive Lymphocyte Crossmatch Heart Transplant: A Strategy to Shorten Left Ventricular Assist Device Support

Journal of Heart and Lung Transplantation

Volumn 27, Issue 9, 2008, Pages 1036-1039

  Lick, Scott D ^a   Vaidya, Smita ^b   Kollar, Andras C ^a   Boor, Paul J ^a   Vertrees, Roger A ^a  

^a University of Texas Medical Branch School of Medicine   (United States)

^b UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; DOBUTAMINE; MILRINONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER;

ADULT; ARTICLE; B LYMPHOCYTE; CASE REPORT; CELL THERAPY; FEMALE; FOLLOW UP; GRAFT DYSFUNCTION; HEART FAILURE; HEART GRAFT; HEART HEMODYNAMICS; HUMAN; INTENSIVE CARE UNIT; LEFT VENTRICULAR ASSIST DEVICE; MALE; MEDICAL INSTRUMENTATION; PLASMAPHERESIS; PRIORITY JOURNAL; T LYMPHOCYTE;

ADULT; ANTIBODIES; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; CARDIOMYOPATHIES; FEMALE; HEART TRANSPLANTATION; HEART-ASSIST DEVICES; HISTOCOMPATIBILITY TESTING; HUMANS; MALE; MIDDLE AGED; PERIOPERATIVE CARE; PLASMAPHERESIS; TREATMENT OUTCOME; VENTRICULAR FUNCTION, LEFT; YOUNG ADULT;

EID: 50249095043     PISSN: 10532498     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.healun.2008.06.004     Document Type: Article

References (28)

1. Joyce D.L., Southard R.E., Torre-Amione G., et al. Impact of left ventricular assist device (LVAD)-mediated humoral sensitization on post-transplant outcomes. J Heart Lung Transplant 24 (2005) 2054-2059
2. Patel P.C., Fitzsimmons C.L., Kaiser P.A., et al. Treatment of HLA sensitized pre-transplant patients with mechanical support is effective for PRA reduction. J Heart Lung Transplant 26 suppl (2007) S104-S105
3. Larson D.F., Elkund D.K., Arabia F., and Copeland J.G. Plasmapheresis during cardiopulmonary bypass: a proposed treatment for presensitized cardiac transplantation patients. J Extra Corpor Technol 31 (1999) 177-183
4. Hale G., Xia M.Q., Tighe H.P., Dyer M.J., and Waldmann H. The CAMPATH-1 antigen (CDw52). Tissue Antigens 35 (1990) 118-127
5. Gilleece M.H., and Dexter T.M. Effect of Campath-1H antibody on human hematopoietic progenitors in vitro. Blood 82 (1993) 807-812
6. Kumar S., Kimlinger T.K., Lust J.A., Donovan K., and Witzig T.E. Expression of CD52 on plasma cells in plasma cell proliferative disorders. Blood 102 (2003) 1075-1077
7. Hale G., Bright S., Chumbley G., et al. Removal of T cells from bone marrow for transplantation: a monoclonal antilymphocyte antibody that fixes human complement. Blood 62 (1983) 873-882
8. Hale G., Swirsky D., Waldmann H., and Chan L.C. Reactivity of rat monoclonal antibody CAMPATH-1 with human leukaemia cells and its possible application for autologous bone marrow transplantation. Br J Haematol 60 (1985) 41-48
9. Rowan W., Tite J., Topley P., and Brett S.J. Cross-linking of the CAMPATH-1 antigen (CD52) mediates growth inhibition in human B- and T-lymphoma cell lines, and subsequent emergence of CD52-deficient cells. Immunology 95 (1998) 427-436
10. Das B., Shoemaker L., Recto M., Austin E., and Dowling R. Alemtuzumab (Campath-1H) induction in a pediatric heart transplant: successful outcome and rationale for its use. J Heart Lung Transplant 27 (2008) 242-244
11. Knechtle S.J., Fernandez L.A., Pirsch J.D., et al. Campath-1H in renal transplantation: the University of Wisconsin experience. Surgery 136 (2004) 754-760
12. Magliocca J.F., and Knechtle S.J. The evolving role of alemtuzumab (Campath-1H) for immunosuppressive therapy in organ transplantation. Transplant Int 19 (2006) 705-714
13. McCurry K.R., Iacono A., Zeevi A., et al. Early outcomes in human lung transplantation with thymoglobulin or Campath-1H for recipient pretreatment followed by posttransplant tacrolimus near-monotherapy. J Thorac Cardiovasc Surg 130 (2005) 528-537
14. Morris P.J., and Russell N.K. Alemtuzumab (Campath 1H): a systematic review in organ transplantation. Transplantation 19 (2006) 705-714
15. Thomas P.G., Woodside K.J., Lappin J.A., et al. Alemtuzumab (Campath 1H) induction with tacrolimus monotherapy is safe for high immunological risk renal transplantation. Transplantation 83 (2007) 1509-1512
16. Zeevi A., Husain S., Spichty K.J., et al. Recovery of functional memory T cells in lung transplant recipients following induction therapy with alemtuzumab. Am J Transplant 7 (2007) 471-475
17. Stewart S., Winters G.L., Fishbein M.C., et al. Revision of the 1990 working formulation for the standardization of nomenclature in the diagnosis of heart rejection. J Heart Lung Transplant 24 (2005) 1710-1720
18. Kaczmarek I., Deutsch M.A., Rohrer M.E., et al. HLA-DR matching improves survival after heart transplantation: is it time to change allocation policies?. J Heart Lung Transplant 25 (2006) 1057-1062
19. Wright E.J., Fiser W.P., Edens R.E., et al. Cardiac transplant outcomes in pediatric patients with pre-formed anti-human leukocyte antigen antibodies and/or positive retrospective crossmatch. J Heart Lung Transplant 26 (2007) 1163-1169
20. Aziz S., Hassantash S.A., Nelson K., et al. The clinical significance of flow cytometry crossmatching in heart transplantation. J Heart Lung Transplant 17 (1998) 686-692
21. Ratkovec R.M., Hammond E.H., O'Connell J.B., et al. Outcome of cardiac transplant recipients with a positive donor-specific crossmatch-preliminary results with plasmapheresis. Transplantation 54 (1992) 651-655
22. Smedira N.G., Hoercher K.J., Feng J., et al. Transplant should not be delayed while awaiting functional recovery in patients on mechanical circulatory support. AATS abstracts 2007. http://www.aats.org/annualmeeting/Abstracts/2007/12.html accessed on 3/20/08
23. Smith J.D., Danskine A.J., Laylor R.M., Rose M.L., and Yacoub M.H. The effect of panel reactive antibodies and the donor specific crossmatch on graft survival after heart and heart-lung transplantation. Transplant Immunol 1 (1993) 60-65
24. Gartner V., Eigentler T.K., and Viebahn R. Plasma cell-rich rejection processes in renal transplantation: morphology and prognostic relevance. Transplantation 81 (2006) 986-991
25. Krukemeyer M.G., Moeller J., Morawietz L., et al. Description of B lymphocytes and plasma cells, complement, and chemokines/receptors in acute liver allograft rejection. Transplantation 78 (2004) 65-70
26. Moeller J., Krukemeyer M.G., Morawietz L., et al. Molecular case report: IgVH analysis in acute humoral and cellular liver allograft rejection suggests a selected accumulation of effector B cells and plasma cells. Virchows Arch 446 (2005) 325-332
27. Zand M.S., Vo T., Huggins J., et al. Polyclonal rabbit antithymocyte globulin triggers B-cell and plasma cell apoptosis by multiple pathways. Transplantation 79 (2005) 1507-1515
28. Woodside K.J., and Lick S.D. Alemtuzumab (Campath 1H) as successful salvage therapy for recurrent steroid-resistant heart transplant rejection. J Heart Lung Transplant 26 (2007) 750-752